LifeSci Venture Partners — Full Portfolio

Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription.

Digital HealthHealthtechMedical DevicesIrvine, US

Edward Damiano(Executive Officer, Director)Sean Saint(President, Chief Executive Officer and Director)inSFStephen Feider(Chief Financial Officer)inMike Mensinger(Chief Product Officer)inSRSteven Russell(Chief Medical Officer)inMHMark Hopman(Chief Commercial Officer)in

Co-investorsWEWellington ManagementOMOmega FundsRTRTW Investments L.P.SOSoleus Capital

Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.

BiotechMedical DevicesBerkeley, US

Jennifer Doudna(Founder)RHRachel Haurwitz(Founder)inMartin Jinek(Founder)Andrew May(Executive Officer)James Berger(Founder)

BoardJRJenny Rooke(Director)in

Co-investorsALAliment CapitalAVAvego BioScience CapitalF-F-Prime CapitalIAIA Seed VenturesMIMission Bay CapitalMIMission Biocapital+3 more

Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer.

AI & Machine LearningBiotechHealthtechMedical DevicesPhiladelphia, US

Osvaldo Flores, Ph.D.(Executive Officer, Director)Douglas Carr(Executive Officer)inBPBrent Pfeiffenberger(President and Chief Executive Officer)inGregory Russotti(Chief Technology and Manufacturing Officer)CCChad Cowan(Chief Scientific Officer)in

BoardToshikazu Ban(Director)

Co-investorsRARA CapitalCACasdin CapitalVEVersant Ventures

Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)GYGary Yeung, CFA(Chief Business Officer)in

BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)

Co-investorsANAndreessen HorowitzARARCH Venture PartnersCOColt VenturesEVEvolution VC PartnersFRFrazier Life SciencesCICity Hill Ventures+1 more

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing product candidates for central nervous system disorders.

BiotechHealthtechWaltham, US

Joseph Reilly(Executive Officer)Geoff Race(Executive Officer)inFred Ahlholm(Executive Officer)inRLRemy Luthringer(Executive Officer, Director)Mark Levine(Executive Officer)

BoardMOMichele Ollier(Director)in

Co-investorsVIVivo CapitalCACare CapitalINIndex VenturesMEMedicxi

Pyxis Oncology develops antibody-drug conjugates and immunotherapies targeting difficult-to-treat cancers to improve patient outcomes.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Thomas Civik(Interim Chief Executive Officer, Director)

BoardDSDavid Steinberg(Executive Officer, Director)inCWChristoph Westphal(Director)GVGeeta Vemuri(Director)inJak Knowles(Director)John Flavin(Director)

Co-investorsAGAgent CapitalLOLongwood FundPFPfizer Venture InvestmentsRARA CapitalTRTrans-Pacific Technology FundRTRTW Investments L.P.

BiotechTel Aviv

Shmuel Cabilly(Director)June Almenoff(Executive Officer)Ofer Tsimchi(Director)Rick D Scruggs(Executive Officer, Director)Nicolas Weinstein(Director)Alla Felder(Director)

PartnerPYPaul Yook· solo GP

Co-investorsHEHEALTHCARE ROYALTY PARTNERS

Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.

BiotechDeep TechMedical DevicesSouth San Francisco, US

TLTim Lu(Co-Founder and Chief Executive Officer)inPLPhilip Lee(Executive Officer)inKanya Rajangam(President, Head of Research & Development and Chief Medical Officer)inYLYvonne Li(Executive Officer)inJames Collins(Director)Timothy Lu(Founder)

Co-investorsEVEvolution VC PartnersFLFlucas VenturesGRGreen Sands EquityLILifeforce CapitalLULux CapitalMEMenlo Ventures+13 more

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.

BiotechHealthtechWest Hartford, US

RWReid Waldman(Chief Executive Officer and Board Member)inTDTim Durso(Chief Technical Officer)inDCDominic Carrano(Chief Financial Officer and Treasurer)inMNMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)

Co-investorsLOLongitude CapitalCOConnecticut InnovationsOUOUP (Osage University Partners)SRSR One Capital ManagementABabrdn plcINInvus

Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space.

BiotechHealthtechMedical Devices

Co-investorsARArboretum VenturesMAMaverick Ventures IsraelVIVisionary VenturesCACatalio Capital ManagementJOJohnson & Johnson Innovation – JJDCSESequoia Capital+1 more

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsATAtlas VentureFOForesite CapitalFRFrazier Life SciencesSCScion Life SciencesTHThe Innovation SpaceVEvenBio Partners+1 more

Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.

BiotechSan Carlos, US

Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)

BoardFCFarah Champsi(Director)inJMJohn McKearn(Director)inPeter Moldt(Director)

Co-investorsALAlta PartnersNENew Enterprise Associates (NEA)RIRiverVest Venture PartnersSASamsara BioCapitalRORoche Venture Fund

Develops novel therapies for rare pediatric neurodegenerative diseases.

Co-investorsASAsahi Kasei Corporate Venture CapitalLGLG Technology VenturesPAPappas Capital

Ambros Therapeutics is a clinical-stage biotechnology company developing medicines for diseases with high unmet medical need, with a lead program targeting complex regional pain syndrome type 1 (CRPS-1), a rare condition typically following limb injury.

BiotechSan Diego, US

J(Joseph (Jay) Hagan(President and Chief Executive Officer)

Co-investorsRARA CapitalBABAM ElevateJAJanus Henderson InvestorsPAPatient Square Capital

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)DMDouglas Mayers(Executive Officer)inTATamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIRIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAIAisling CapitalALAltium CapitalAVAvego BioScience CapitalPOPontifax Venture CapitalAMAmzak HealthDEDelos Capital+8 more

A biotechnology company developing new therapies for patients with high unmet medical needs.

Biotech

Co-investorsDODolby Family VenturesSOSofinnova VenturesTHThe W FundVIViking GlobalCOCommodore CapitalFRFranklin Templeton+6 more

Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.

BiotechHealthtechSouth San Francisco, US

JWJonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)MTMark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)RKRahul Kakkar(Director)inGreg Bell(Executive Officer)

Co-investorsALAlpha Wave GlobalBIBioBritVEvenBio PartnersJAJanus Henderson InvestorsREREDMILESASamsara BioCapital+2 more

Augmedix builds AI-driven documentation technology for clinicians, aiming to reduce time spent on technology so providers can focus on patient care.

AI & Machine LearningDigital HealthHealthtechSan Francisco, US

Ian Shakil(Executive Officer, Director)inPTPelu Tran(Cofounder)inEKEmmanuel Krakaris(Executive Officer, Director)inPaul Ginocchio(Executive Officer)inSandra Breber(Executive Officer)inJoseph Marks(Director)

Co-investorsDCDCM VenturesEVEvolution VC PartnersGRGreat Oaks Venture CapitalOVOVO FundSASand Hill AngelsSTStartX+3 more

Averto Medical is developing a medical device intended to improve care for patients undergoing colorectal surgery.

HealthtechMedical Devices

Biolinq develops glucose-sensing technology based on micro-array biosensors for metabolic health monitoring, including continuous glucose monitoring.

BiotechDigital HealthHardwareHealthtechMedical DevicesSan Diego, US

JTJared Tangney(Co-founder)inRYRich Yang(Co-founder)inEdward Kliphuis(Director)

BoardDBDaniel Bradbury(Director)inLGLana Ghanem(Director)

Co-investorsALAlpha Wave GlobalRIRiverVest Venture PartnersABAble PartnersAPAphelion CapitalAVAverin CapitalBEBeyond Capital+7 more

Bright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform.

BiotechDeep TechHealthtechNew York, US

Alan Kozikowski(Executive Officer, Director)inIan McDonaldRyan Cheung(Chief Financial Officer)JAN PEDERSEN(Chief Science Officer)Gideon Shapiro(Executive Officer)Revati Sheeniwas(Executive Officer)

Co-investorsPAPalo Santo VCPSPsyMed Ventures

Cala Health develops non-invasive prescription therapies for movement disorders, starting with a treatment for hand tremor and essential tremor.

Deep TechDigital HealthHealthtechMedical DevicesSilicon Valley, US

KRKate Rosenbluth, PhD(President & Chief Innovation Officer)KRKate Rosenbluth(Founder)inDHDeanna Harshbarger(Founder)in

Co-investorsALAlumni VenturesASAscension VenturesGLGlobal BrainGVGV (Google Ventures)LILightstone VenturesLULux Capital+5 more

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

KSKen Song(Chairman, President and CEO)inKSKenneth Song, M.D.(Executive Officer, Director)AKArvind Kush(Executive Officer)TLTimothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsFOForesite CapitalOROrbiMedSASamsara BioCapitalTCTCG CrossoverTHThird Rock VenturesVEvenBio Partners+2 more

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsADAdvent Life SciencesECEcoR1 CapitalFOForesite CapitalMEMedicxiOBOberland CapitalSCScion Life Sciences+4 more

BiotechCambridge, US

CAChad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)

BoardMartin Murphy(Director)

Co-investorsBABain Capital Life SciencesCACasdin CapitalVEVenrock Healthcare Capital Partners

Cannabis retailer operating dispensaries across Maryland, New York, Ohio, and Pennsylvania.

ConsumerRetail Tech

Co-investorsARArtemis Growth Partners

Crescent Biopharma is an oncology-focused biopharmaceutical company developing cancer treatments aimed at establishing new standards of care for patients living with cancer.

Biotech

Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.

BiotechBrookline, US

Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)

BoardGMGeorge M. Church(Director)

Co-investorsALAlta PartnersARARCH Venture PartnersCACatalio Capital Management, LPHBHBM Healthcare InvestmentsHBHBM PartnersKHKhosla Ventures+13 more

Company whose formation and launch the LifeSci team supported.

BiotechHealthtechSummit, US

Gregory Mayes(Executive Officer, Director, Promoter)Jouko Isojarvi(Executive Officer)Stephen D. Collins(Director)WLWarren Lammert(Director)inOrrin Devinsky(Director)

BoardGBGerry Brunk(Director)in

PartnerPYPaul Yook· solo GP

Co-investorsLULumira VenturesRERed Tree Venture

Iridia develops Molecular Avatar Technology that embeds unalterable molecular identities and custom data (text, image, audio, or video) into physical products and materials such as paints, coatings, plastics, and liquids.

BiotechDeep TechNew Materials

PartnerPYPaul Yook· solo GP

Co-investorsATATEM Capital FundCOConnecticut InnovationsDUDuke Capital PartnersLOLongley CapitalWEWestern Digital CapitalPRPrime Movers Lab

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKBKristina Burow(Director)inRHRichard Heyman(Director)inANAmir Nashat(Director)in

Co-investorsAGage1ECEcoR1 CapitalLALAVLILilly Asia VenturesNENew Enterprise Associates (NEA)VIVivo Capital+8 more

Minerva Labs was an Israeli endpoint security company whose anti-evasion platform prevented malware by simulating hostile environments to deter evasive threats.

Cybersecurity

Co-investorsACAccelmed PartnersAMAmplify PartnersSASaints CapitalSTStageOne VenturesWEWebb Investment NetworkGLGlencrest Group

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAPAsit Parikh(Chief Executive Officer)in

Co-investorsNENextech InvestTHThird Rock VenturesALAlexandriaCACasdin CapitalCRCreacion VenturesGOGoldman Sachs+3 more

Acquired by Genmab in April 2024.

Co-investorsB B Capital GroupB4B4 CapitalHOHongShan Capital GroupLALAVLILilly Asia VenturesLYLYFE Capital+2 more

RayzeBio develops radiopharmaceutical therapies for cancer treatment.

BiotechHealthtechMedical DevicesSan Diego, US

KSKen Song(Executive Officer, Director)inBHBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)

BoardARAaron Royston(Director)in

Co-investorsSASamsara BioCapitalSCScion Life SciencesSOSofinnova VenturesTCTCG CrossoverVEvenBio PartnersVEVersant Ventures+4 more

Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders.

BiotechDigital HealthMedical Devices

GSGaurav Shah(Co-founder & Chief Executive Officer)in

BoardRoderick Wong(Director)inNYNaveen Yalamanchi(Director)in

Co-investorsAVAvoro Capital AdvisorsBRBroadview VenturesCICivilization Ventures Management, LlcFRFrazier Life SciencesRTRTW Investments L.P.

Science37 operates a decentralized clinical trial platform supported by a network of medical directors across specialties including cardiology, neurology, psychiatry, pediatrics, and internal medicine.

BiotechDigital HealthHealthtechMedical Devices

TVTyler Van Horn(Chief Executive Officer)inDWDebra Weinstein(Chief Medical Officer)in

Co-investorsGLGlynn Capital ManagementGVGV (Google Ventures)LULux CapitalSASanofi VenturesINInertia VenturesREREDMILE

Vyne Therapeutics is a biopharmaceutical company developing treatments for Graves' disease and thyroid eye disease (TED).

Biotech

Co-investorsF-F-Prime Capital

WorkStep (WorkHound) is an AI-powered employee engagement platform for frontline and distributed workforces, offering surveys, AI-generated responses to feedback, targeted communications, and predictive insights.

AI & Machine LearningHR TechSaaSChattanooga, US

MFMax Farrell(CEO)inAndrew Kirpalani(Executive Officer, Director)Elizabeth Engel(Director)

Co-investorsDIDivide by ZeroDYDynamo VenturesGRGrand VenturesLELevel EquityLILightyearSPSpringTime Ventures+2 more